Search Result
Results for "
PC-3
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-146985
-
|
Cathepsin
|
Neurological Disease
Cancer
|
Cathepsin X-IN-1 (compound 25) is a potent Cathepsin X inhibitor with an IC50 of 7.13 µM. Cathepsin X-IN-1 decreases PC-3 cell migration with low cytotoxic .
|
-
-
- HY-153910
-
|
Others
|
Cancer
|
AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
|
-
-
- HY-149976
-
|
Pim
|
Cancer
|
Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor (IC50: 17.01 nM). Pim-1 kinase inhibitor 4 also has antioxidant activity and inhibits DPPH. Pim-1 kinase inhibitor 4 induces apoptosis in PC-3 cell, and inhibits PC-3 cell growth with an IC50 of 16 nM. Pim-1 kinase inhibitor 4 can be used for research of prostate cancer .
|
-
-
- HY-N4029
-
|
Others
|
Cancer
|
Humulene oxide II is an essential oil component from Zingiber striolatum Diels flowers, leaves and stems. Humulene oxide II has cytotoxicity against A549, PC-3 and K562 cell lines .
|
-
-
- HY-155610
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .
|
-
-
- HY-108361
-
|
Ras
|
Inflammation/Immunology
Cancer
|
CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
|
-
-
- HY-162380
-
|
Topoisomerase
|
Cancer
|
Topoisomerase II inhibitor 18 (Compound IV) is a Quinoxaline derivative, which inhibits topoisomerase II with IC50 of 7.5 μM. Topoisomerase II inhibitor 18 inhibits proliferation, cell cycle at S phase and induces apoptosis in PC-3 cells. Topoisomerase II inhibitor 18 reveals antitumor activity against cancer .
|
-
-
- HY-W778562
-
|
Others
|
Cancer
|
10-Deacetyl-13-oxobaccatin III is an taxane that can be isolated from Taxus sumatrana. 10-Deacetyl-13-oxobaccatin III (30 μg/mL) shows cytotoxicity against A498, NCI-H226, A549, PC-3 cells, with inhibition a rate of 29.7%, 49.2%, 43.9%, 65.3% .
|
-
-
- HY-107640
-
|
MMP
|
Cancer
|
WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC50 of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research .
|
-
-
- HY-N12004
-
|
Others
|
Cancer
|
19-Hydroxy-10-deacetylbaccatin III (compound 13) is a taxane with potential antitumor activity. 19-Hydroxy-10-deacetylbaccatin III has weak cytotoxicity against A498 and NCI-H226 cell lines. The study found that the inhibition rates of 30 μg/mL 19-Hydroxy-10-deacetylbaccatin III on A498, NCI-H226 and PC-3 were 16.6% and 32% respectively .
|
-
-
- HY-144808
-
|
Others
|
Cancer
|
Anticancer agent 40 (compound 3e) is a potent anticancer agent. Anticancer agent 40 shows anticancer activities with IC50s of 0.94, 0.98, 0.96, 0.95, 2.13 nM for SKBR-3, SKOV-3, PC-3, U-87, HDF cells, respectively .
|
-
-
- HY-122678
-
|
Survivin
Apoptosis
|
Cancer
|
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 µM, respectively .
|
-
-
- HY-142958
-
-
-
- HY-146038
-
|
Apoptosis
ROS Kinase
MDM-2/p53
Bcl-2 Family
|
Cancer
|
Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC50 of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3 .
|
-
-
- HY-147854
-
|
Raf
Apoptosis
|
Cancer
|
B-Raf IN 9 (compound 8b) is a potent B-Raf inhibitor, with an IC50 of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC50 of 7.83 µM .
|
-
-
- HY-121619
-
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC50 is 11.8 μM), LNCaP (IC50 is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator [3]. Jacaric acid is orally active.
|
-
-
- HY-147853
-
|
Raf
|
Cancer
|
B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC50 of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52 and 29.85 µM .
|
-
-
- HY-149091
-
|
Others
|
Cancer
|
KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .
|
-
-
- HY-147852
-
|
Raf
|
Cancer
|
B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .
|
-
-
- HY-13626
-
ES-285
|
PKC
|
Cancer
|
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation .
|
-
-
- HY-N7019
-
|
Others
|
Cancer
|
19-Hydroxybufalin is a bufadienolide, inhibits epithelial-mesenchymal transition and attenuates the migration and invasion of PC3 cells .
|
-
-
- HY-143641
-
|
Others
|
Cancer
|
Anticancer agent 25 exhibits the strongest cytotoxicity against PC3 cells with an IC50 value of 0.19 μM.
|
-
-
- HY-N10687
-
NSC 648341
|
Others
|
Cancer
|
Saprorthoquinone (NSC 648341) is a diterpenoid that can be found in salvia atropatana. Saprorthoquinone shows cytotoxicity for PC3 cells .
|
-
-
- HY-130709
-
|
PROTACs
CDK
|
Cancer
|
PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .
|
-
-
- HY-13626S
-
|
Isotope-Labeled Compounds
PKC
|
Cancer
|
Spisulosine-d3 is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC
|
-
-
- HY-N7972
-
|
Others
|
Cancer
|
19-Oxocinobufotalin is capable of suppressing EMT (Epithelial-mesenchymal transition) and weakening the migratory and invasive potential of PC3 cells .
|
-
-
- HY-143882
-
|
PROTACs
Akt
|
Cancer
|
MS5033 is a potent PROTAC-based AKT (protein kinase B) degrader, with a DC50 of 430 nM in PC3 cells .
|
-
-
- HY-141863
-
|
Apoptosis
|
Cancer
|
Lepidozin G inhibits the growth of a panel of cancer cell lines with IC50 values ranging from 4.2 ± 0.2 to 5.7 ± 0.5 μM. Lepidozin G induces PC-3 cell death via mitochondrial-related apoptosis.
|
-
-
- HY-162304
-
|
MAGL
|
Neurological Disease
|
MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC50 of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively .
|
-
-
- HY-149632
-
|
EGFR
Dihydrofolate reductase (DHFR)
|
Cancer
|
EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor of EGFR, HER2, and DHFR (IC50: 0.248, 0.156, 0.138 μM respectively). EGFR/HER2/DHFR-IN-2 has anticancer activities against a panel of cancer cells (IC50: 9.14, 7.33, 14.18, 24.87, 20.07, 6.16 μM for Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7 cells). EGFR/HER2/DHFR-IN-2 reduce breast cancer tumor growth .
|
-
-
- HY-12842
-
|
IAP
Apoptosis
|
Cancer
|
UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).
|
-
-
- HY-N11651
-
|
Others
|
Others
|
Peganumine A is a natural product that can be found in Peganum harmala. Peganumine A shows cytotoxicity with IC50s of5.8, 38.5, 40.2, 55.4 µM for HL-60, MCF-7, PC-3, and HepG2 cells ,respectively .
|
-
-
- HY-RS05193
-
|
Small Interfering RNA (siRNA)
|
Others
|
G6PC3 Human Pre-designed siRNA Set A contains three designed siRNAs for G6PC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
G6PC3 Human Pre-designed siRNA Set A
G6PC3 Human Pre-designed siRNA Set A
-
- HY-101947
-
SMI-16a
3 Publications Verification
PIM1/2 Kinase Inhibitor VI
|
Pim
|
Cancer
|
SMI-16a is a selective Pim kinase inhibitor with IC50 values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.
|
-
-
- HY-12364
-
C75
Maximum Cited Publications
21 Publications Verification
|
Fatty Acid Synthase (FASN)
|
Cancer
|
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM [3]. C75 is a potent CPT1A activator .
|
-
-
- HY-14307
-
|
Others
|
Cancer
|
Necrocide 1 (compound (S)-38) a potent anticancer agent. Necrocide 1 has antiproliferative activity with an IC50 value of 0.48 and 2 nM for MCF-7 and PC3, respectively .
|
-
-
- HY-147100
-
|
PROTACs
Adrenergic Receptor
|
Cancer
|
α1A-AR Degrader 9c (compound 9c) is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC50 of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC50 of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research .
|
-
-
- HY-158025
-
|
DNA/RNA Synthesis
|
Cancer
|
Anticancer agent 198 (compound 18b) is a potent anticancer agent and potential WRN protein inhibitor. Anticancer agent 198 was significantly toxic to K562 cells and WRN-overexpressing PC3 cells .
|
-
-
- HY-147734
-
|
Others
|
Cancer
|
Calpain inhibitors are lipophilic and show moderate to good antiproliferative activity in vitro compared with melanoma cell lines (a-375 and b-16f1) and PC-3 prostate cancer cells. In addition, a member of this group (compound 3) expressed 2 μ M concentration inhibited the invasion of DU-145 cells by 80%.
|
-
-
- HY-156778
-
|
Others
|
Cancer
|
Antitumor agent-120 (compound 1) is a flavonoid compound isolated from Kudzu root.Antitumor agent-120 has no significant inhibitory activity against LNCaP and PC3 cancer cells, with IC50s >50 μM .
|
-
-
- HY-132197
-
|
Epigenetic Reader Domain
Histone Acetyltransferase
|
Cancer
|
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC50 of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC50 of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .
|
-
-
- HY-12364B
-
|
Fatty Acid Synthase (FASN)
|
Cancer
|
(−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM [3]. C75 is a potent CPT1A activator .
|
-
-
- HY-103385
-
NO-Aspirin
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects .
|
-
-
- HY-155718
-
|
Apoptosis
|
Cancer
|
fac-[Re(CO)3(L6)(H2O)][NO3] (compound 6), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L6)(H2O)][NO3] is cytotoxic to prostate cancer cells, IC50=50 nM (PC-3 cells). fac-[Re(CO)3(L6)(H2O)][NO3] mainly accumulates in the nucleus, down-regulates ATP production in PC3 cells, and promotes apoptosis. However, fac-[Re(CO)3(L6)(H2O)][NO3] did not induce necrosis, pyrodeath and autophagy .
|
-
-
- HY-13847
-
|
mTOR
|
Cancer
|
GNE-555 is a selective, metabolically stable mTOR inhibitor (Ki=1.5 nM) that also has good oral bioavailability. GNE-555 exhibits antiproliferative activity on PC3 and MCF-7 cells and can be used in cancer research .
|
-
-
- HY-146170
-
|
Reactive Oxygen Species
EGFR
Apoptosis
|
Cancer
|
Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC50=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis .
|
-
-
- HY-154861
-
|
Bacterial
Apoptosis
Necroptosis
|
|
Anticancer agent 118, a N‑acylated ciprofloxacin derivative, has anti-bacterial and anticancer activities. Anticancer agent 118 shows high activity against Gram-positive strains and antiproliferative activities against prostate PC3 cells. Anticancer agent 118 can be used for antitumor research .
|
-
-
- HY-149715
-
|
ICMT
|
Cancer
|
R1-11 is an indole ICMT inhibitor with an IC50 of 0.6 μM and has anticancer activity. R1-11 inhibits MDA-MB231 and PC3 cells with IC50s of 2.2 μM and 2.0 μM, respectively .
|
-
-
- HY-155719
-
|
Paraptosis
|
Cancer
|
fac-[Re(CO)3(L3)(H2O)][NO3] (compound 3), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L3)(H2O)][NO3] is cytotoxic to prostate cancer cells with IC50=0.32 μM (PC-3 cells). fac-[Re(CO)3(L3)(H2O)][NO3] mainly accumulates in mitochondria, down-regulates ATP production in PC3 cells, and promotes paraptosis. However, fac-[Re(CO)3(L3)(H2O)][NO3] did not induce necrosis, apoptosis and autophagy .
|
-
-
- HY-149729
-
|
ICMT
|
Cancer
|
ICMT-IN-53 (compound 12) is an ICMT inhibitor (IC50=0.96 μM) with PAMPA permeability and antiproliferative activity. ICMT-IN-53 inhibits the proliferation of MDA-MB-231 and PC3 with IC50s of 5.14 μM and 5.88 μM, respectively .
|
-
- HY-143883
-
|
Akt
|
Cancer
|
MS143 is a potent AKT degrader (DC50=46 nM and GI50=0.8 µM in PC3 cells). MS143 induces rapid and robust AKT degradation in a concentration- and time-dependent manner via hijacking the ubiquitin-proteasome system. MS143 can suppress cancer cell growth .
|
-
- HY-100186
-
|
Androgen Receptor
|
Cardiovascular Disease
Others
Metabolic Disease
Inflammation/Immunology
Endocrinology
Cancer
|
GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness [3] .
|
-
- HY-119257
-
|
Farnesyl Transferase
Apoptosis
|
Cancer
|
ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .
|
-
- HY-138633
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 1.3 nM and 18 nM, respectively .
|
-
- HY-138636
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-13 (compound 9d) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-13 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.025 nM and 6.0 nM, respectively .
|
-
- HY-138632
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.86 nM and 7.6 nM, respectively .
|
-
- HY-138555
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
|
-
- HY-138634
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.23 nM and 0.38 nM, respectively .
|
-
- HY-138635
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.39 nM and 0.24 nM, respectively .
|
-
- HY-138637
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-14 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-14 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
|
-
- HY-139294
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
|
-
- HY-N12466
-
|
PKC
p38 MAPK
ROCK
|
Cancer
|
3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine (Compound 7) is an inhibitor of protein kinases, with IC50s of 0.092, 0.26, 0.77 μM for PKC-α, ROCK, ASK1. 3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine shows potent cytotoxicity against PC-3 cancer cells with an IC50 value of 0.16 μM .
|
-
- HY-149995
-
|
Pim
|
Cancer
|
Pim-1 kinase inhibitor 5 (Compound 4c) is a Pim-1 kinase inhibitor (IC50: 0.61 μM). Pim-1 kinase inhibitor 5 shows cytotoxicity against cancer cells, with IC50s of 6.95-20.19 μM for HepG2, MCF-7, PC3, and HCT-116 cells .
|
-
- HY-157404
-
|
Pim
|
Cancer
|
Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
|
-
- HY-115959
-
|
Bacterial
|
Inflammation/Immunology
Cancer
|
Anticancer agent 34 (compound 9), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 34 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/ml. Anticancer agent 34 inhibits A549, PC3 cell growth with IC50s of 8.4 µg/ml, 7.8 µg/ml, respectively .
|
-
- HY-115961
-
|
Bacterial
|
Inflammation/Immunology
Cancer
|
Anticancer agent 36 (compound 11), a sulfonylurea derivative, is a potent antimicrobial and anticancer agent. Anticancer agent 36 inhibits the microbial growth of B. mycoides, E. coli, and C. albicans with a MIC between 0.156 and 0.039 mg/L. Anticancer agent 36 inhibits A549, PC3 cell growth with IC50s of 19.7 µg/mL, 11.9 µg/mL, respectively .
|
-
- HY-N1107
-
NSC 119993; NSC 277290; Odorigeni
|
Others
|
Cancer
|
Uzarigenin (NSC 119993; NSC 277290; Odorigeni) is a carnolide can be isolated from Pergularia tomentosa and exhibits antiproliferative activity. Uzarigenin resists the proliferation of PC3 cells, HeLa cells, Calu-1 cells, MCF-7 cells and U251MG cells, with IC50 values of 0.3 μM, 3.0 μM, 8.0 μM, 6.0 μM and 6.0 μM respectively .
|
-
- HY-115974
-
|
Others
|
Cancer
|
GRPR antagonist-1 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC50 of 4.97, 4.36 and 3.40 μM in PC3, Pan02 and HGC-27 cells, respectively). GRPR antagonist-1 inhibits HGC-27 cell viability by decreasing the Bcl-2 level and increasing the Bax level, causing apoptosis. Anticancer activity .
|
-
- HY-16160
-
|
Autophagy
ICMT
|
Cancer
|
Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research [3].
|
-
- HY-157125
-
|
PI3K
Apoptosis
|
Cancer
|
PI3Kα-IN-14 (compound F8) is a selective PI3Kα inhibitor with an IC50 of 0.14 nM. PI3Kα-IN-14 induces a great decrease in mitochondrial membrane which caused cell cycle arrest at G1 phase and apoptosis in U87-MG cells. PI3Kα-IN-14 shows significant anti-proliferative activities against three tumor-derived cell lines (PC-3: IC50 of 0.28 μM; HCT-116: IC50 of 0.57 μM; and U87-MG: IC50 of 1.37 μM) .
|
-
- HY-147696
-
|
HSP
AMPK
Reactive Oxygen Species
|
Cancer
|
SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
|
-
- HY-18696
-
|
c-Met/HGFR
Caspase
Apoptosis
|
Cancer
|
AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis .
|
-
- HY-N7535
-
|
Others
|
Cancer
|
Chlorovaltrate K is a chlorinated valepotriate with anticancer effects. Chlorovaltrate K shows moderate cytotoxicity against A549, PC-3M, HCT-8 and Bel 7402 cell lines with IC50 values of 2.32-8.26 μM .
|
-
- HY-N1762
-
|
Fungal
|
Cancer
|
3α,22β-Dihydroxyolean-12-en-29-oic acid is a terpenoid that can be isolated from Maytenus royleanus cufodontis .
|
-
- HY-125747
-
Actinomycin V
|
Bacterial
Antibiotic
Apoptosis
|
Infection
Cancer
|
Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .
|
-
- HY-146539
-
|
HDAC
VEGFR
|
Cancer
|
HDAC-IN-35 (Compound 14) is a potent, selective HDAC and VEGFR-2 inhibitor, with IC50 values of 0.166 and 13.2 µM for HDAC6 and VEGFR-2, respectively .
|
-
- HY-146200
-
|
PI3K
mTOR
|
Cancer
|
PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and mTOR dual inhibitor with IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase .
|
-
- HY-144760
-
|
EGFR
Apoptosis
|
Cancer
|
EGFR-IN-3 (Compound 4c) is a potent EGFR inhibitor with an IC50 of 0.32 µM against EGFRwt-TK. EGFR-IN-3 shows cytotoxic activity against cancer cell lines and induces apoptosis .
|
-
- HY-W748509
-
|
Caspase
Apoptosis
|
Cancer
|
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .
|
-
- HY-149293
-
|
E1/E2/E3 Enzyme
|
Cancer
|
Skp2 inhibitor 1 (compound 14i) is a potent and selective Skp2 inhibitor against the Skp2-Cks1 interaction with an IC50 of 2.8 μM. Skp inhibitor 1 exhibits anticancer activity .
|
-
- HY-P5580
-
|
Bacterial
|
Infection
Cancer
|
Dermaseptin-B3 inhibits the growth of Gram-positive and Gram-negative bacteria (MIC: 1.3, 2.3, 5.0, 2.6, 2.3 μM for S. aureus, P. aeruginosa, P. aeruginosa, E. (ATCC 25922), E. (54127) respectively). Dermaseptin-B3 also inhibits tumor cell proliferation .
|
-
- HY-107336
-
Beveno
|
COX
|
Inflammation/Immunology
|
Cyclovalone (Beveno) is a synthetic curcumin derivate, which inihibits cyclooxygenase and exhibits anti-inflammatory, antitumor and antioxidant activities . Cyclovalone inhibits cell proliferation in normal and malignant prostatic cells. Cyclovalone ist orally active .
|
-
- HY-119665
-
|
AMPK
mTOR
|
Cancer
|
Asteltoxin is an inhibitor for extracellular vesicles (EV), which exhibits inhibitory effects towards mitochondrial ATP synthase and mTORC1 activation .
|
-
- HY-17037
-
LS 519; Pirenzepin dihydrochloride; Gastrozepin dihydrochloride
|
mAChR
|
Metabolic Disease
Cancer
|
Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells .
|
-
- HY-123091
-
|
Others
|
Cancer
|
Ivangustin is a sesquiterpene isolated from the flower heads of the medicinal plant Inula britannica .
|
-
- HY-149000
-
|
PI3K
Apoptosis
|
Cancer
|
PI3Kα-IN-7 (Compound A12) is a potent PI3Kα inhibitor. PI3Kα-IN-7 also inhibits PI3Kβ. PI3Kα-IN-7 decreases cancer cells mitochondrial membrane potential and induces apoptosis .
|
-
- HY-N10491
-
|
P-glycoprotein
|
Cancer
|
Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer .
|
-
- HY-N10492
-
|
P-glycoprotein
|
Cancer
|
Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer .
|
-
- HY-17037S1
-
LS 519-d8 dihydrochloride; Pirenzepin-d8 dihydrochloride; Gastrozepin-d8 dihydrochloride
|
Isotope-Labeled Compounds
|
Cancer
|
Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells [3].
|
-
- HY-149616
-
|
PROTACs
ERK
|
Cancer
|
PPM-3 is a potent and selective PROTAC ERK5 degrader, with an IC50 of 62.4 nM. PPM-3 did not influence tumor cell growth directly. PPM-3 influences tumor development by affecting the differentiation of macrophages .
|
-
- HY-157561
-
-
- HY-19625A
-
|
Reactive Oxygen Species
|
Cancer
|
(E/Z)-MCB-613 is a pan-Steroid Receptor Coactivator (SRC) stimulator. (E/Z)-MCB-613 overstimulates SRC activity in cancer cells resulting in excessive generation of reactive oxygen species (ROS), leading to cell stress and death by a process called paraptosis. (E/Z)-MCB-613 is a cytotoxic molecule that plays an important role in cancer .
|
-
- HY-N12606
-
|
Fungal
|
Infection
|
Neodidymelliosides A (compound 1)It is a secondary metabolite of fungi and has a significant inhibitory effect on Staphylococcus aureus and Candida albicans biofilms. Neodidymelliosides AIt also has anti-cancer activity and can inhibit KB3.1 (cervix),PC-3 (prostate),MCF-7(breast),SKOV-3 (ovary),A431 (skin )and A549 (lung )Cell viability of cell lines .
|
-
- HY-N6952
-
-
- HY-144744
-
|
NF-κB
|
Cancer
|
NF-κB-IN-3 (Compound 2) is a NF-κB inhibitor with an IC50 of 0.70 µM. NF-κB-IN-3 can be used as an antitumor agent .
|
-
- HY-146396
-
|
Others
|
Cancer
|
Anticancer agent 51 (compound 3d) is a potent anticancer agent with an Ki of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer .
|
-
- HY-151477
-
|
SARS-CoV
|
Infection
Cancer
|
SARS-CoV-2-IN-32 (compound 3g) is a COVID-19 inhibitor. SARS-CoV-2-IN-32 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-32 exhibits comparatively high binding affinity (-8.8 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-32 can be used in studies of cancer and COVID-19 .
|
-
- HY-151478
-
|
SARS-CoV
|
Infection
Cancer
|
SARS-CoV-2-IN-33 (compound 3m) is a COVID-19 inhibitor. SARS-CoV-2-IN-33 shows anti-proliferative activity against cancer cells. SARS-CoV-2-IN-33 exhibits comparatively good binding affinity (-8.0 Kcal/mole) to COVID-19 main protease (M pro) (PDB ID: 6LU7). SARS-CoV-2-IN-33 can be used in studies of cancer and COVID-19 .
|
-
- HY-152091
-
|
Fungal
|
Infection
Cancer
|
Antiproliferative agent-18 (Compound 5k) is an anti-proliferative agent. Antiproliferative agent-18 also displays moderate anti-bacterial and anti-fungi activity .
|
-
- HY-P99802
-
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-N0986
-
|
Others
|
Cancer
|
1,4,5,6-Tetrahydroxy-7-(3-methylbut-2-enyl)xanthone is a nature product that could be isolated from the stem barks of Garcinia xanthochymus. 1,4,5,6-Tetrahydroxy-7-(3-methylbut-2-enyl)xanthone has antiproliferative active. 1,4,5,6-Tetrahydroxy-7-(3-methylbut-2-enyl)xanthone can be used in research of cancer .
|
-
- HY-162319
-
|
Apoptosis
HDAC
Microtubule/Tubulin
Reactive Oxygen Species
|
Cancer
|
Tubulin/HDAC-IN-4 (compound 9n) is a dual Tubulin and HDAC inhibitor with IC50 values of 0.73, 0.43, 0.62, 2.34 µM for HDAC1, HDAC2, HDAC6, HDAC7, respectively. Tubulin/HDAC-IN-4 inhibits the tubulin polymerization by targeting the colchicine binding site. Tubulin/HDAC-IN-4 induces apoptosis and cell cycle arrest at G2/M phase. Tubulin/HDAC-IN-4 induces a significant elevation of intracellular ROS levels. Tubulin/HDAC-IN-4 shows anti-angiogenesis activity and anticancer activity .
|
-
- HY-133558
-
|
E1/E2/E3 Enzyme
Apoptosis
|
Cancer
|
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .
|
-
- HY-120574
-
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
TH1338 (compound 3b), an orally active camptothecin derivative and a potent chemotherapeutic agent for cancer, demonstrates excellent cytotoxic potency against human tumor cell lines in vitro. TH1338 (compound 3b) possesses significant brain penetration, favorable efflux pump properties, and hematological toxicity profile .
|
-
- HY-111207
-
|
CDK
Apoptosis
|
Cancer
|
CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
|
-
- HY-147874
-
-
- HY-122844
-
BI-853520; IN-10018
|
FAK
|
Cancer
|
Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively [3].
|
-
- HY-118798
-
NSC663285
|
Phosphatase
|
Cancer
|
DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer .
|
-
- HY-163062
-
|
Microtubule/Tubulin
Apoptosis
Complement System
|
Cancer
|
Tubulin/NRP1-IN-1 (compound TN-2) is a dual inhibitor of Tubulin and NRP1 with IC50s of 0.71 and 0.85 μM, respectively. Tubulin/NRP1-IN-1 significantly inhibits the viability of prostate tumor cell lines and induces apoptosis .
|
-
- HY-129932
-
|
Others
|
Cancer
|
Pyrrolidine ricinoleamide ((R)-5d) is a fatty acid amide that exhibits effective antiproliferative activity against a series of cancer cells, including human glioma U251 cells. Pyrrolidine ricinoleamide can be used in cancer research .
|
-
- HY-16187
-
|
HIF/HIF Prolyl-Hydroxylase
Apoptosis
|
Cancer
|
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .
|
-
- HY-12003
-
|
Aurora Kinase
|
Cancer
|
SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively .
|
-
- HY-13991
-
|
Ras
Apoptosis
|
Cancer
|
CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes [3].
|
-
- HY-108344
-
|
Aurora Kinase
|
Cancer
|
SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively .
|
-
- HY-150500
-
|
HDAC
|
Cancer
|
HDAC-IN-44 is a HDAC inhibitor with the IC50 value of 61.2 nM. HDAC-IN-44 shows high anticancer activity towards multiple cancer cell lines .
|
-
- HY-151474
-
|
SARS-CoV
|
Cancer
|
SARS-CoV-2-IN-31 is an effective COVID-19 inhibitor. SARS-CoV-2-IN-31 exhibits excellent to mild activity against various cancer cell lines with IC50 values range from 28.84 to 38.36 μM. SARS-CoV-2-IN-31 can be used for the research of cancer .
|
-
- HY-108566
-
U-46619
2 Publications Verification
9,11-Methanoepoxy PGH2
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .
|
-
- HY-151161
-
|
EGFR
|
Cancer
|
EGFR/HER2-IN-8 (compound 34) is a EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC50s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .
|
-
- HY-151156
-
|
EGFR
Apoptosis
|
Cancer
|
EGFR/HER2-IN-6 (compound 43) is an EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-6 inhibits EGFR kinase, HER2 kinase and DHFR with IC50s of 0.122, 0.078 and 0.585 μM, respectively. EGFR/HER2-IN-6 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer .
|
-
- HY-149968
-
|
Histone Demethylase
Apoptosis
|
Cancer
|
LSD1-IN-25 (Compound 9j) is a potent, selective and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis .
|
-
- HY-162264
-
|
Microtubule/Tubulin
Proton Pump
Apoptosis
|
Inflammation/Immunology
Cancer
|
Tubulin polymerization/V-ATPase-IN-1 (compound F10) is a Tubulin polymerization/V-ATPase inhibitor. Tubulin polymerization/V-ATPase-IN-1 shows robust antiproliferation activity against four human cancer cell lines, and exerts antiproliferative activity by inhibiting tubulin and V-ATPase. Tubulin polymerization/V-ATPase-IN-1 induces immunogenic cell death in addition to apoptosis, and inhibits tumor growth in an RM-1 homograft model with enhanced T lymphocyte infiltration .
|
-
- HY-125727
-
|
Fungal
|
Infection
Cancer
|
Globosuxanthone A is a dihydroxanthenone with obvious antifungal activity towards Fusarium graminearum, Fusarium solani, and Botrytis cinerea with MIC values of 4, 8, and 16 μg/mL, respectively. Anticancer activity .
|
-
- HY-123295
-
|
HDAC
|
Infection
Cancer
|
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC50 of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .
|
-
- HY-133147
-
|
HDAC
Apoptosis
|
Cancer
|
HDAC3/6-IN-2 (compound 15) is a potent HDAC6 and HDAC3 inhibitor, with IC50 values of 0.368 and 0.635 μM, respectively. HDAC3/6-IN-2 shows antitumor activity, and induces cancer cell apoptosis. HDAC3/6-IN-2 decreases the levels of HDAC6 and HDAC3, associated with upregulation of acetylated H3 and α-tubulin .
|
-
- HY-146433
-
|
Apoptosis
|
Cancer
|
Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer .
|
-
- HY-13610
-
|
Caspase
|
Cancer
|
N1,N11-Diethylnorspermine (DENSPM) is a potent anticancer agent. N1,N11-Diethylnorspermine is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production [3].
|
-
- HY-123611
-
RX-5902
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC50s ranging from 10 nM to 20 nM .
|
-
- HY-16446
-
|
c-Met/HGFR
PI3K
Akt
MEK
Apoptosis
|
Cancer
|
SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer [3].
|
-
- HY-163340
-
|
Glucocorticoid Receptor
Androgen Receptor
|
Cancer
|
GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC50 values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .
|
-
- HY-149283
-
|
JAK
HDAC
Apoptosis
|
Cancer
|
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-125747
-
Actinomycin V
|
Bacterial
Antibiotic
Apoptosis
|
Infection
Cancer
|
Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of MRSA with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .
|
-
- HY-P5831
-
|
Peptides
|
Cancer
|
Biotin-H10 is a specific anterior gradient homolog 2 (AGR2) inhibitor with a KD of 6.4 nM. Biotin-H10 inhibits cancer cells viability .
|
-
- HY-P3320
-
PC 3
|
Peptides
|
Others
|
Phytochelatin 3 (PC 3) is the small metal chelating peptide that can be used for chelating heavy metals .
|
-
- HY-P3320A
-
PC 3 TFA
|
Peptides
|
Others
|
Phytochelatin 3 (PC 3) TFA is the small metal chelating peptide that can be used for chelating heavy metals .
|
-
- HY-P5580
-
|
Bacterial
|
Infection
Cancer
|
Dermaseptin-B3 inhibits the growth of Gram-positive and Gram-negative bacteria (MIC: 1.3, 2.3, 5.0, 2.6, 2.3 μM for S. aureus, P. aeruginosa, P. aeruginosa, E. (ATCC 25922), E. (54127) respectively). Dermaseptin-B3 also inhibits tumor cell proliferation .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99802
-
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17037S1
-
|
Pirenzepine-d8 (LS 519-d8; Pirenzepin-d8) dihydrochloride is a deuterium labeled Pirenzepine (dihydrochloride) (HY-17037). Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells [3].
|
-
-
- HY-13626S
-
|
Spisulosine-d3 is deuterium labeled Spisulosine. Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKC
|
-
Cat. No. |
Product Name |
Application |
Reactivity |
-
- HY-P80556
-
APG3; APG3L; PC3-96; APG3-LIKE
|
WB, IHC-F, IHC-P, ICC/IF
|
Human, Mouse, Rat |
ATG3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 36 kDa, targeting to ATG3. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.
|
-
- HY-P82941
-
PC3; ARP1B; CTRN2
|
WB, IHC-F, IHC-P, ICC/IF, IP
|
Human |
Cat. No. |
Product Name |
|
Classification |
-
- HY-157880
-
Azido-PC
|
|
Azide
|
N3-PC (Azido-PC) is a photoactivatable phosphatidylcholine that can be used in the synthesis of cell membrane structures. N3-PC (Azido-PC) is a click chemistry reagent containing an azide group .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: